Skip to main content
RIGL logo

RIGL · Rigel Pharmaceuticals Inc · Documents

Track RIGL — free
$42.53 -0.39 (-0.91%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$800.84M
Shares
18.83M
Volume · Nov 18 304.84K Avg daily vol (3M) 252.93K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $294.28M up 64.1% 10-K filed Mar 3, 2026 Quarterly report FY2026 Q3 Revenue $80.89M up 16.5% 10-Q filed Nov 5, 2026 Latest results VEPPANU generates $6.6 million in initial sales 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 17
Investor event
Vepenew Sales Reach 6.6 Million in First Six Weeks

Rigel said Vepenew, acquired in June and launched in mid-August, generated 6.6 million in sales in its first six weeks. Net product sales of 72 million in the past quarter were the company's largest quarterly figure ever. The company plans to present updated R289 data at the ASH meeting in December and start a registrational study in 2027 with FDA concurrence.

7 source passages
The deal closed in June. In the first six weeks, it launched mid-August. We were able to achieve 6.6 million in sales, a really impressive number. This past quarter, we achieved 72 million in net product sales, our largest quarterly sales number ever. R289 is our IRAC-1 and 4 inhibitor in development in a Phase 1b study for relapse refractory lower-risk MDS. We will have updated data on the dose expansion phase at the ASH meeting in December in a few weeks. Our plan is to start the registrational study in 2027 with FDA concurrence on this. Open the document at this passage
Nov 5
Earnings call
Vepenu launch drives 13% product sales growth

Rigel generated $72.3 million in net product sales for the third quarter of 2026, up 13% year-over-year, including $6.6 million from Vepenu.

3 source passages
our net product sales were $72.3 million for the third quarter of 2026, an increase of 13% compared to the third quarter of 2025, primarily driven by the addition of Vepinu during the third quarter. Vepenu net product sales of $6.6 million, reflecting approximately six weeks of commercial availability. Rigel's Open the document at this passage
Nov 5
Current report 8-K
VEPPANU generates $6.6 million in initial sales

Rigel reported third-quarter total revenues of $80.9 million and net income of $13.2 million, while VEPPANU generated $6.6 million in initial net product sales. It updated the 2026 revenue outlook to approximately $290 to $295 million, excluding VEPPANU.

Financial results
5 source passages
For the third quarter ended September 30, 2026, total revenues were $80.9 million, consisting of $72.3 million in net product sales and $8.6 million in contract revenues from collaborations. Rigel reported net income of $13.2 million, or $0.70 basic and $0.65 diluted per share, compared to $27.9 million, or $1.55 basic and $1.46 diluted per share, for the same period of 2025. Rigel announced that VEPPANU (vepdegestrant) became commercially available in the U.S. on August 13, 2026, generating $6.6 million in net product sales in the third quarter. Rigel has updated its 2026 total revenues guidance to approximately $290 to $295 million, from the previous range of approximately $285 to $295 million, which includes: The above revenue guidance excludes VEPPANU. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
VEPPANU launches with $6.6 million in initial sales

VEPPANU generated $6.6 million in initial net product sales from its August 13, 2026 launch through September 30, 2026, while nine-month TAVALISSE sales rose 15% to $130.6 million.

Revenue $80.89M ▲ 16.5% Net income $13.19M ▼ 52.7% Diluted EPS $0.65 ▼ 55.5%
Read from the MD&A section
2 source passages
VEPPANU is our fourth FDA-approved product which we began commercializing on August 13, 2026, with initial net product sales of $6.6 million from launch through September 30, 2026. TAVALISSE net product sales for the nine months ended September 30, 2026 were $130.6 million, an increase of $17.4 million, or 15%, compared with $113.3 million for the same period in 2025. Open the document at this passage
Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $78.7M ▼ 22.6% Net income $17.29M ▼ 71.0% Diluted EPS $0.88 ▼ 73.2%
May 5
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $58.82M ▲ 10.3% Net income $8.65M ▼ 24.4% Diluted EPS $0.44 ▼ 30.2%
Apr 3
Proxy statement DEF 14A Meeting May 14, 2026
Proxy statement AI summary on its way
Mar 3
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $294.28M ▲ 64.1% Net income $367.02M ▲ 1999.1% Diluted EPS $19.48 ▲ 1867.7%
2025
Nov 4
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $69.46M ▲ 25.6% Net income $27.9M ▲ 124.6% Diluted EPS $1.46 ▲ 108.6%
Mar 4
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $179.28M ▲ 53.4% Net income $17.49M Diluted EPS $0.99
2024
Showing 1–50 of 155 documents
Key facts CIK 1034842 CUSIP 766559702 13F (30d) 182 filings 156 filers Visit website Investor relations